ADIM
DNLI icon

Alpha DNA Investment Management’s Denali Therapeutics DNLI Stock Holding History

Alpha DNA Investment Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-79
Closed -$4K – 242
2021
Q1 		$4K Buy
79
+17
+27% +$1.14K ﹤0.01% 401
2020
Q4 		$5K Buy
+62
New +$3.75K 0.01% 362

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Alpha DNA Investment Management's DNLI Position: Q2 2021 in Review

Alpha DNA Investment Management sold out of Denali Therapeutics (DNLI) in Q2 2021, closing a stake of 79 shares — an estimated $4K sold.

Alpha DNA Investment Management first reported a position in DNLI in Q4 2020 and held it in 2 quarters. The position peaked at $5K in Q4 2020. 210 funds tracked by Wall St. Rank hold DNLI as of Q2 2021.

  • Alpha DNA Investment Management reported no remaining Denali Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Alpha DNA Investment Management sold 79 Denali Therapeutics shares in Q2 2021, an estimated $4K.
  • Alpha DNA Investment Management first reported a position in Denali Therapeutics in Q4 2020 and held it in 2 quarters.
  • Alpha DNA Investment Management's Denali Therapeutics position peaked at $5K in Q4 2020.
  • 210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2021.

Based on Alpha DNA Investment Management's 13F filing for Q2 2021, filed 10 Aug 2021.